Research programme: proteostasis regulators - Proteostasis Therapeutics

Drug Profile

Research programme: proteostasis regulators - Proteostasis Therapeutics

Alternative Names: PTI 808; PTI NC 733; PTI-130; PTI-801 - Proteostasis Therapeutics; PTI-C1811; PTI-P271

Latest Information Update: 21 Oct 2016

Price : $50

At a glance

  • Originator Proteostasis Therapeutics
  • Developer Biogen; Cystic Fibrosis Foundation Therapeutics; Harvard Medical School; Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Cystic fibrosis transmembrane conductance regulator stimulants; Protein folding modulators; Protein modulators; USP14 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease; Cystic fibrosis; Neurodegenerative disorders
  • Research Inflammation; Metabolic disorders; Parkinson's disease

Most Recent Events

  • 30 Mar 2017 Proteostasis Therapeutics plans to file an IND application with the US FDA for Cystic fibrosis
  • 30 Mar 2017 Proteostasis Therapeutics plans a phase I trial for Cystic fibrosis
  • 11 Aug 2016 Proteostasis Therapeutics announces intention to submit IND applications for PTI 801 and PTI 808 to US FDA in December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top